Roche has commercially launched the cobas HIV-1/HIV-2 test for use on the automated cobas 6800/8800 Systems in countries that accept CE mark.

Designed to qualitatively detect and differentiate HIV-1 from HIV-2, the new test is expected to enable healthcare professionals to provide treatment options depending on the subtype infections.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The in-vitro nucleic acid amplification test is approved for plasma and serum to enable flexible PCR testing and its dried blood spot (DBS) collection card has also been authorised as a sample type to facilitate testing in rural areas.

The test also includes a dual target technology for the detection of HIV-1 and can be used to confirm the infection in an individual with specimens reactive for HIV-1 or HIV-2 antibodies or antigens.

Roche Molecular Diagnostics head Uwe Oberlaender said: "As the leader in HIV diagnostics, Roche is committed to providing technologies to help providers and patients improve their treatment decisions.

"The ability to more accurately differentiate subtype infection is a significant advancement in controlling and eradicating the HIV/AIDS epidemic."

"The ability to more accurately differentiate subtype infection is a significant advancement in controlling and eradicating the HIV/AIDS epidemic."

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The greater sensitivity of PCR technology of the test is expected to minimise the period of detection to around one week compared to the duration of two and four weeks required by existing tests.

Based on PCR technology, the fully integrated and automated cobas 6800 and cobas 8800 systems are designed for molecular testing in viral load monitoring, donor screening, women's health, and microbiology.

In addition to the new cobas HIV-1/HIV-2, the systems can accommodate various molecular assays such as cobas HCV, cobas HBV, cobas CMV, cobas HPV, cobas MPX, cobas WNV, and cobas HEV.

Image: cobas 6000-analysis module. Photo: courtesy of F Hoffmann-La Roche Ltd.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact